Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04637763 | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) | unknown | Phase 1 | 72 | Caribou Biosciences, Inc.INDUSTRY | 3 | Mar 24, 2025 | clinicaltrials |
| NCT02716012 | First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer(OUTREACH) | unknown | Phase 1 | 75 | Mina Alpha LimitedINDUSTRY | 3 | Mar 10, 2025 |
| clinicaltrials |
| NCT06454175 | A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years | unknown | Phase 1 | 72 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 6, 2025 | clinicaltrials |
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06250244 | 177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 12 | Peking Union Medical College HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06585527 | Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma | unknown | Phase 1 | 30 | Beijing Neurosurgical InstituteOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06590194 | PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 1 / Phase 2 | 96 | Suzhou Puhe Pharmaceutical Technology Co., LTDINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03225417 | Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. | unknown | Phase 1 / Phase 2 | 142 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT03557619 | A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies | unknown | Phase 1 | 12 | AbbVieINDUSTRY | 2 | Aug 29, 2024 | clinicaltrials |
| NCT05272293 | Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML | unknown | Phase 1 / Phase 2 | 15 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05333302 | Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma | unknown | Phase 1 | 10 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05334693 | Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML | unknown | Phase 1 / Phase 2 | 15 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06224387 | CTS2190 Phase I /II Clinical Study in Patients | unknown | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT05867303 | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | unknown | Phase 1 | 48 | RemeGen Co., Ltd.INDUSTRY | 2 | Aug 16, 2024 | clinicaltrials |
| NCT05222087 | PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer - A Pilot Study(PRIME_LUNG) | unknown | Phase 1 | 40 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06556004 | Phase 1 Study Using TRIMELVax for Stage IIIC / IV Melanoma Patients(Trimelvax001) | unknown | Phase 1 | 20 | University of ChileOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT04682808 | A Study of FCN-338 in Patients With Chronic CLL/SLL | unknown | Phase 1 | 99 | Fochon Pharmaceuticals, Ltd.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06463522 | Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 20 | Beijing 302 HospitalOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT04914741 | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)(COALITION) | unknown | Phase 1 / Phase 2 | 80 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06006390 | CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06479473 | Radiotherapy to All Residual Lesions After Chemoimmunotherapy | unknown | Phase 1 / Phase 2 | 150 | Anhui Provincial HospitalOTHER_GOV | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06545630 | Tumor Antigen-sensitized DC Vaccine for Colorectal Cancer Liver Metastases | unknown | Phase 1 | 10 | West China HospitalOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05749549 | Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers | unknown | Phase 1 / Phase 2 | 191 | Shanghai Blueray Biopharma Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT03631953 | Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas(ALTREM) | unknown | Phase 1 | 25 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT04220944 | Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. | unknown | Phase 1 | 45 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06526832 | A Phase 1 Study of BST02 in Treating Locally Advanced Liver Cancer | unknown | Phase 1 | 9 | BioSyngen Pte LtdINDUSTRY | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06527495 | Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 150 | Assiut UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT05842785 | TSN222 in Subjects With Advanced Solid Tumors or Lymphomas | unknown | Phase 1 / Phase 2 | 162 | Tyligand Bioscience (Shanghai) LimitedINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT04823403 | Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma(HIPANIV) | unknown | Phase 1 | 27 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06520319 | Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma | unknown | Phase 1 | 20 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jul 25, 2024 | clinicaltrials |
| NCT05803928 | Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies | unknown | Phase 1 | 70 | Hua LiOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06237491 | The Safety and Dosimetry Study of 177Lu-LNC1003 Injection | unknown | Phase 1 | 12 | Yantai LNC Biotechnology Singapore PTE. LTD.INDUSTRY | 0 | Jul 24, 2024 | clinicaltrials |
| NCT06256055 | Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors | unknown | Phase 1 | 24 | UTC Therapeutics Inc.INDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06109207 | Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas | unknown | Phase 1 | 6 | West China HospitalOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT05183243 | GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results | unknown | Phase 1 | 68 | Suzhou Genhouse Bio Co., Ltd.OTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05271292 | Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.(SCLC) | unknown | Phase 1 / Phase 2 | 36 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06503094 | CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors | unknown | Phase 1 / Phase 2 | 80 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06503211 | On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma | unknown | Phase 1 | 10 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT04365179 | Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML | unknown | Phase 1 | 18 | Immune System Key LtdINDUSTRY | 1 | Jul 10, 2024 | clinicaltrials |
| NCT06362980 | A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations(EGFR) | unknown | Phase 1 | 20 | National Cancer Center, ChinaOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT03784066 | Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity(DUTRELASCO) | unknown | Phase 1 / Phase 2 | 21 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT02628405 | R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma | unknown | Phase 1 / Phase 2 | 30 | Academic and Community Cancer Research UnitedOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT04432857 | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | unknown | Phase 1 | 63 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 2 | Jun 27, 2024 | clinicaltrials |
| NCT06478381 | L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma | unknown | Phase 1 | 22 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 27, 2024 | clinicaltrials |
| NCT05060432 | Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors(TIG-006) | unknown | Phase 1 / Phase 2 | 153 | iTeos Belgium SAINDUSTRY | 6 | Jun 21, 2024 | clinicaltrials |
| NCT05444088 | Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 129 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 21, 2024 | clinicaltrials |
| NCT02977468 | Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer(Pembro/IORT) | unknown | Phase 1 | 15 | Eileen ConnollyOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT05422027 | Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma | unknown | Phase 1 / Phase 2 | 42 | Xia ZhongjunOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT05816499 | Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)(AK104IIT018) | unknown | Phase 1 / Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Jun 17, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Mar 24, 2025source: clinicaltrials